ERBB2 and breast carcinoma: We recently described the distribution and five-year survival of the subtypes of breast cancer based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [6,7], and found wide variation in survival especially among the HER2-positive group of patients.